<DOC>
	<DOCNO>NCT02909933</DOCNO>
	<brief_summary>Weight reduction important treatment target polycystic ovary syndrome ( PCOS ) link obesity . Liraglutide ( LIRA ) dose 3 mg recently approve anti-obesity drug . Metformin could enhance weight lower potential liraglutide . We investigate short term intervention low dose liraglutide combination metformin high dose liraglutide alone influence significant weight reduction obese woman PCOS .</brief_summary>
	<brief_title>Low Dose Liraglutide Metformin vs. High Dose Liraglutide Alone Treatment Obesity</brief_title>
	<detailed_description />
	<mesh_term>Obesity</mesh_term>
	<mesh_term>Polycystic Ovary Syndrome</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>18 year old menopause polycystic ovary syndrome ( NICHD criterion ) BMI 30 kg/mÂ² high type 1 type 2 diabetes mellitus history carcinoma Cushing 's syndrome congenital ( nonclassic ) adrenal hyperplasia personal family history MEN 2 significant cardiovascular , kidney hepatic disease use medication know suspected affect reproductive metabolic function use statin , within 90 day prior study entry</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>